Advanced search×

Accessibility to targeted oncology drugs in Slovenia and selected European countries

Mitja M Kos, Marko M Obradovic, and Ales A Mrhar

Eur J Cancer 44(3):11 (2008) PMID 18155900

Aim: The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods: Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated. Results: The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries. Conclusion: The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.

DOI: 10.1016/j.ejca.2007.11.020
Version: za2963e q8za4 q8zb8 q8zc8 q8zd5 q8zea q8zfd q8zg9

Similar articles you may find interesting…

  1. Introducing radiotherapy to Oman.
    Bidhu Kalyan BK Mohanti

    Eur J Cancer 44(3):333 (2008) PMID 18437722

  2. Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherap...
    Maura M Massimino, Lorenza L Gandola, ... Maria Luisa ML Garrè

    Int J Radiat Oncol Biol Phys 80(3):807-14 (2011) PMID 20646868

    Our results confirm poor rates of event-free survival and overall survival for up-front chemotherapy in infant ependymoma. No better neurocognitive outcome was demonstrated in the few survivors who never received RT. Copyright © 2010 Elsevier Inc. All rights reserved....
  3. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Russell P RP Rother, Scott A SA Rollins, ... Leonard L Bell

    Nat Biotechnol 25(11):1256-64 (2007) PMID 17989688

    The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinosit...